{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:25:02Z","timestamp":1788380702586,"version":"build-2803163510"},"reference-count":26,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Post Reprod Health"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Studies investigating the safety of hormone replacement therapy in cervical cancer have predominantly included patients with squamous disease. Pathological studies have identified estrogen receptor positivity in cervical adenocarcinomas. A recent small case-control study suggested a trend towards reduced survival with hormone replacement therapy in cervical adenocarcinomas. Our objective was to determine if hormone replacement therapy use in patients treated for cervical adenocarcinomas is detrimental to survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>A retrospective review of all women under the age of 50 with stage 1B-2B cervical adenocarcinomas diagnosed between 1 November 2000 and 24 September 2019. Women were categorised into three groups: ovaries conserved (OVCON); or iatrogenic menopause with (IM-HRT) or without (IM-NOHRT) hormone replacement therapy. Hormone replacement therapy use was defined on an intention to treat basis. Statistical analysis was performed using Kaplan-Meier and Cox proportional hazards methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Overall (OS), disease specific (DSS) and progression free (PFS) survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 58 women (mean age 38.5\u2009\u00b1\u20096.6) were included in the study of whom 25 (43.1%) had OVCON, 20 (34.4%) had IM-HRT and 13 (22.4%) had IM-NOHRT. No menopause-associated deaths occurred. Although five-year DSS was 73% in IM-NOHRT compared to 95% in IM-HRT and 95% in OVCON, these differences were not statistically significant. Five-year PFS was 68% in IM-NOHRT compared to 90% in IM-HRT and 81% in OVCON but again, these differences were not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small study, hormone replacement therapy does not appear to be detrimental to survival in cervical adenocarcinomas. There is a trend towards improved survival with hormone replacement therapy. Larger studies are required to substantiate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20533691211028518","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T13:30:24Z","timestamp":1626183024000},"page":"167-173","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1098-6945","authenticated-orcid":false,"given":"A","family":"Richardson","sequence":"first","affiliation":[{"name":"Department of Gynaecology, University Hospitals of Leicester NHS Trust, University Hospitals of Leicester NHS Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Watson","sequence":"additional","affiliation":[{"name":"Derby Gynaecological Cancer Centre, University Hospitals of Derby and Burton NHS Foundation Trust, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Persic","sequence":"additional","affiliation":[{"name":"Derby Gynaecological Cancer Centre, University Hospitals of Derby and Burton NHS Foundation Trust, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Phillips","sequence":"additional","affiliation":[{"name":"Derby Gynaecological Cancer Centre, University Hospitals of Derby and Burton NHS Foundation Trust, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"bibr1-20533691211028518","unstructured":"Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cervical-cancer"},{"key":"bibr2-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000263"},{"key":"bibr3-20533691211028518","first-page":"380","volume-title":"Textbook of gynaecological oncology","author":"Scott M.","year":"2017","edition":"4"},{"key":"bibr4-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(87)90270-8"},{"key":"bibr5-20533691211028518","first-page":"1341","volume":"30","author":"Bodner K","year":"2010","journal-title":"Anticancer Res"},{"key":"bibr6-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12949-2"},{"key":"bibr7-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5731"},{"key":"bibr8-20533691211028518","doi-asserted-by":"publisher","DOI":"10.5468\/ogs.2018.61.5.584"},{"key":"bibr9-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1080\/13697130902780846"},{"key":"bibr10-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.09.009"},{"key":"bibr11-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2020.1851183"},{"key":"bibr12-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.1992.02060332.x"},{"key":"bibr13-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00348.x"},{"key":"bibr14-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2009.11.017"},{"key":"bibr15-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1258\/175404507781605622"},{"key":"bibr16-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.5.925"},{"key":"bibr17-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.13.1465"},{"key":"bibr18-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.11.1851"},{"key":"bibr19-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92592-1"},{"key":"bibr20-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03868.x"},{"key":"bibr21-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(59)92129-4"},{"key":"bibr22-20533691211028518","doi-asserted-by":"publisher","DOI":"10.3109\/01674820009075624"},{"key":"bibr23-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000276984.19542.e6"},{"key":"bibr24-20533691211028518","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000165392.35273.d4"},{"key":"bibr25-20533691211028518","unstructured":"ESHRE. Management of women with premature ovarian insufficiency. Available from https:\/\/www.eshre.eu\/Guidelines-and-Legal\/Guidelines\/Management-of-premature-ovarian-insufficiency2015."},{"key":"bibr26-20533691211028518","doi-asserted-by":"crossref","unstructured":"Richardson A, Ayres J, Cust M, et al. Hormone replacement therapy following treatment of gynaecological malignancies.\n                      The Obstetrician and Gynaecologist\n                      2019; 21: 291-298","DOI":"10.1111\/tog.12607"}],"container-title":["Post Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20533691211028518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20533691211028518","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20533691211028518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:25:38Z","timestamp":1766517938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20533691211028518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1177\/20533691211028518"],"URL":"https:\/\/doi.org\/10.1177\/20533691211028518","relation":{},"ISSN":["2053-3691","2053-3705"],"issn-type":[{"value":"2053-3691","type":"print"},{"value":"2053-3705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]}}}